Anocca is creating a pipeline of precision T-cell immunotherapies by combining its novel approach to T-cell biology, cutting-edge biotechnologies and integrated software.

Anocca

Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity.
 
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. 
 
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

European Investment Bank

Swedbank Robur’s Ny Teknik

Nidoco

Ramsbury Invest AB

Harald Mix

Robert Andreen

Swedbank Robur

Mellby Gård AB

Michano

We’re kicking-off 2024 with exciting news! We are pleased to announce that Anocca has secured a GMP manufacturing license from the Swedish Medical Products Agency for our in-house #CellTherapy facility, the largest in the Nordics.

This key regulatory milestone reinforces our commitment to precision #immunotherapy and paves the way for clinical development of Anocca’s #KRAS #TCRT product franchise.

KRAS driver mutations are responsible for aggressive #cancer forms and TCR-T is a therapeutic modality with the potential to transform patient outcomes. 

Manufactured with a next-gen autologous approach, we're set to initiate clinical trials later this year in hard-to-treat solid tumour indications.

🔗Read the full press release here: https://lnkd.in/e5vp4SY3

Anocca is hiring - Are you our Corporate Business Controller?

We are seeking a highly motivated operational Business Controller to join our team. The role allows exposure to all key aspects of financial management and operations. The ideal candidate will have a proven track record of managing financial operations, performing financial analysis, and providing insights to senior management.

The Business Controller will work closely with Anocca’s CFO, Finance organisation and Senior Leadership team and will play a critical role in supporting the company in its transformation from a leading research to clinical stage organisation.

The role is full-time and located at our headquarters in Södertälje.

More information is here: https://lnkd.in/dzBvHW8

Meet our CEO Reagan Jarvis at the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024.

We’re open to #partnering and #investor meetings to discuss how our deep asset pipeline and novel technologies can help patients.

Anocca’s platform decodes the complexity of T cell biology and enables development of powerful engineered TCR-T #immunotherapies for hard-to-treat solid #tumour indications. 

📧: Schedule a meeting with us at #JPM2024: bd@anocca.com

#biotech #celltherapy #cellandgenetherapy

Our CDO, Mark Farmery will be delivering a key session at Cell & Gene Therapy Manufacturing & Commercialization Europe, from December 4 – 6 in Dublin, Ireland!

📅11:05 – 11:40 | December 5 | Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies

Learn how Anocca leverages its precision biology discovery platform and advanced in-house manufacturing capabilities to decode the complexity of the human immune system and encode and develop powerful engineered TCR-T cell #immunotherapies for hard-to-treat solid #cancer indications.

Connect with Mark there to discuss how we are preparing to take our first highly validated TCR-T product builds into clinical development using the partnering system: https://lnkd.in/ezGrMkME

🔗 Join #CellGene 2023: https://lnkd.in/eeWBzXk

Informa Connect Life Sciences

#biotech #celltherapy #cellandgenetherapy

DNSSEC

Font Awesome

Organization Schema

CrUX Dataset

CrUX Top 50m

PostalAddress Schema

COVID-19

Ruby on Rails Token

Visa

Digital Ocean

Chief Business Officer

Brian McGee

Head of Operations

Viktor Arnkil

HR Manager

Mikael Pedin

Clinical Operations Manager

Rehab Alnabhan

Head of Process Development

Anette Brass

Bioengineer

Athina Totomi

Software Engineer

Biniam Palaiologos

Junior Software Engineer - Frontend

Efthymios Karakasis

Engineering

Francesca Aloisio, PhD

Hannes Uchtenhagen

Reagan Jarvis

CEO and Co-Founder

Jacob Michlewicz

Nordic Countries Companies With Fewer Than 1000 Employees (Top 10K)

Sweden Companies With Less Than $50M in Revenue (Top 10K)

Europe, Middle East, and Africa (EMEA) Companies (Top 10K)

European Union (EU) Companies With Less Than $500M in Revenue (Top 10K)

Anocca provides services like biotechnology, immunotherapeutics, drug discovery, drug development, and immunology services.

The company does precise and efficient analysis of T-cell biology, which is required to deliver a variety of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, assisting the life sciences sector in developing a variety of therapies and vaccination strategies.

Anocca was established on October 23, 2014 by Reagan Jarvis in Södertälje, Vasternorrlands Lan.

Venture Round - Anocca

Debt Financing - Anocca

Series B - Anocca

Computer and Software Services and Scientific Services

Södertälje

Vasternorrlands Lan

Sweden

Europe

Anocca Appoints Christiane Hanke-Harloff to Board of Directors

Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in ...

Anocca AB and Shinobi Therapeutics Announce Strategic

EmendoBio enters a licensing agreement for its gene editing technology with Anocca AB

Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.

Anocca to license EmendoBio's gene editing technology

Engineered T-cell receptor therapies designed to recognize and target cancer cells, aiming to treat various types of untreatable cancers.

A software platform that models T-cell biology, enabling data storage, organization, analysis, visualization, and automation for T-cell therapy development.

A comprehensive pipeline of TCR-T cell therapies targeting diverse cancer types and patient groups, currently in various stages of development.

Development of T-cell therapies for diseases beyond oncology, including infectious diseases, autoimmunity, and allergies.

Germany

Canada

North America

The Netherlands

Belarus

Developing neoantigen-targeted cell therapies using bioinformatic analyses of patients’ tumor and normal DNA and RNA

Pact Pharma Inc.

An innovative therapeutic biotechnology company developing next-generation immunotherapies that precisely leverage the immune system of each patient.

news impact assignment basic	general	Feb 13, 2024 10:18 AM	8c7a3f84
public peers	general	Oct 2, 2024 1:59 PM	950e6f04
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 13, 2024 10:18 AM	b96d8cd1
company summary	general
signals	general	Oct 2, 2024 1:59 PM	b24f0d95
crunchbase trigger	general	Nov 25, 2024 9:06 AM	47d0b28a
crunchbase profile	general	Nov 25, 2024 9:45 AM	62e0d85d
li profile	general	Feb 13, 2024 10:18 AM	8e44da9a
translate crunchbase fundingrounds	general	Nov 25, 2024 1:49 PM	b1afe03f
peers	general	Oct 2, 2024 1:59 PM	10b4b72f
news basic	general	Oct 2, 2024 1:59 PM	7ba29f98
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ANOCCA

Anocca